TP53 and neoplasm: The authors also demonstrated that Hsp90 stabilized mup53, and adding the Hsp90 inhibitor, ganetespib, increased median survival in tumor-bearing mice possessing either the R248Q or the R172H (R175H in humans) p53 mutants by 59% and 48%, respectively, with no effect on p53-null mice.